LPCN vs. ORGS, CEMI, TNXP, LPTX, LTRN, VERU, RPTX, CYBN, SCPH, and RAPT
Should you be buying Lipocine stock or one of its competitors? The main competitors of Lipocine include Orgenesis (ORGS), Chembio Diagnostics (CEMI), Tonix Pharmaceuticals (TNXP), Leap Therapeutics (LPTX), Lantern Pharma (LTRN), Veru (VERU), Repare Therapeutics (RPTX), Cybin (CYBN), scPharmaceuticals (SCPH), and RAPT Therapeutics (RAPT). These companies are all part of the "pharmaceutical preparations" industry.
Lipocine (NASDAQ:LPCN) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, community ranking, media sentiment, analyst recommendations and dividends.
In the previous week, Lipocine had 1 more articles in the media than Orgenesis. MarketBeat recorded 3 mentions for Lipocine and 2 mentions for Orgenesis. Orgenesis' average media sentiment score of 1.66 beat Lipocine's score of 0.85 indicating that Orgenesis is being referred to more favorably in the news media.
Lipocine received 342 more outperform votes than Orgenesis when rated by MarketBeat users. However, 100.00% of users gave Orgenesis an outperform vote while only 70.14% of users gave Lipocine an outperform vote.
Lipocine has higher earnings, but lower revenue than Orgenesis.
9.1% of Lipocine shares are held by institutional investors. Comparatively, 22.6% of Orgenesis shares are held by institutional investors. 6.1% of Lipocine shares are held by company insiders. Comparatively, 5.7% of Orgenesis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Lipocine has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, Orgenesis has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.
Lipocine has a net margin of 0.00% compared to Orgenesis' net margin of -1,343.97%. Lipocine's return on equity of -37.62% beat Orgenesis' return on equity.
Summary
Lipocine beats Orgenesis on 8 of the 13 factors compared between the two stocks.
Get Lipocine News Delivered to You Automatically
Sign up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LPCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lipocine Competitors List
Related Companies and Tools
